Psychedelic Research in
South Africa
Blossom currently tracks 6 psychedelic clinical trials connected to South Africa. The country page also links to 1 stakeholder, giving the page ecosystem context beyond registered studies.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in South Africa.
- 1
Blossom tracks 6 psychedelic clinical trials connected to South Africa, with none currently marked active.
- 2
Visible trial compounds include Esketamine.
- 3
Visible trial topics include Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
- 4
The country page links to 1 stakeholder in Blossom's ecosystem data.
- 5
The country access guide currently classifies access as "Medical Only (Private)"; details vary by compound and care setting.
Research Snapshot
Blossom currently tracks 6 psychedelic clinical trials connected to South Africa.
- Active trials
- 0
- Total trials
- 6
- Stakeholders
- 2
- Events
- 0
None marked active
Country-linked records
Linked organisations
No linked events
Top Compounds
- Esketamine(6)
Top Study Topics
- Treatment-Resistant Depression (TRD)(4)
- Major Depressive Disorder (MDD)(2)
Medical Access Snapshot
South Africa maintains a restrictive, medically-regulated approach to classic and novel psychedelics. Ketamine is an established medical anesthetic and is used off-label for depression in specialist settings; esketamine (Spravato) has been reported as available through registered channels. Most classical serotonergic psychedelics (psilocybin, MDMA, DMT, 5-MeO-DMT, mescaline, 2C-X) and sacramental preparations (ayahuasca) remain controlled with no routine reimbursed medical availability outside authorised research or tightly regulated exemptions.
Regulatory Status
The linked medical access and reimbursement guide summarises South Africa as "Medical Only (Private)". South Africa maintains a restrictive, medically-regulated approach to classic and novel psychedelics. Ketamine is an established medical anesthetic and is used off-label for depression in specialist settings; esketamine (Spravato) has been reported as available through registered channels.
Country Details
- Region
- Africa
- Last updated
- 4 May 2026
Country Report
Medical Only (Private)Medical Access and Reimbursement
South Africa maintains a restrictive, medically-regulated approach to classic and novel psychedelics. Ketamine is an established medical anesthetic and is used off-label for depression in specialist settings; esketamine (Spravato) has been reported as available through registered channels. Most...
Open access guide →Psychedelic Stakeholders in South Africa
Organisations, sponsors, clinics, and research groups connected to psychedelic science in South Africa.
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in South Africa.